Sangkaara vairavan for Bronchial asthma
Phase 2
- Conditions
- Health Condition 1: J454- Moderate persistent asthma
- Registration Number
- CTRI/2024/05/068028
- Lead Sponsor
- Dr R Sasirekha
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Cough with tenacious sputum
Dyspnea
H/O Wheeze or without wheeze
Chest tightness
Peak expiratory flow rate between 60-80%
Exclusion Criteria
K/C/O Chronic bronchitis
K/C/O Bronchiectasis
K/C/O Pulmonary TB
K/C/O Congestive cardiac failure
K/C/O Status asthmaticus
Pregnancy and lactating mothers
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does Sangkaara vairavan target in moderate persistent asthma (J454) according to Siddha medicine principles?
How does the efficacy of Siddha medicine Sangkaara vairavan compare to standard-of-care bronchodilators and anti-inflammatory agents in J454 asthma patients?
Are there specific biomarkers in bronchial asthma subtypes that correlate with response to Sangkaara vairavan treatment in phase II trials?
What adverse events are associated with Siddha formulation Sangkaara vairavan in chronic respiratory disease management and how are they managed?
What combination therapies or competitor drugs in bronchial asthma treatment align with the therapeutic approach of Sangkaara vairavan in Siddha medicine?